cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30462818
title: Supplementary Material for: A Novel KMT5B Frameshift Variant Presenting with Autism and Psychiatric Features: Intra-Familial Phenotypic Variation – A Case Report

description: Pathogenic variants in the KMT5B gene, encoding a lysine methyltransferase involved in chromatin remodeling, have been associated with intellectual disability, autism spectrum disorder, and various dysmorphic features. However, the detailed genotype-phenotype correlations have yet to be fully elucidated. We report a four-year-old male patient who presented with developmental delay, impaired social interaction, repetitive behaviors, and language delay. Whole-exome sequencing identified a novel heterozygous frameshift variant in KMT5B (c.618del; p.Glu206Aspfs*7). Segregation analysis revealed that the patient's father also carried the same variant and exhibited intellectual disability and obsessive-compulsive disorder. This expands the mutational and phenotypic spectrum associated with KMT5B haploinsufficiency. It also underscores the potential for neuropsychiatric manifestations of KMT5B-related disorders to persist into adulthood, emphasizing the need for long-term follow-up and broader neurobehavioral assessment in affected individuals.
DOI: 10.6084/m9.figshare.30462818.v1
title: Supplementary Material for: A Novel KMT5B Frameshift Variant Presenting with Autism and Psychiatric Features: Intra-Familial Phenotypic Variation – A Case Report

description: Pathogenic variants in the KMT5B gene, encoding a lysine methyltransferase involved in chromatin remodeling, have been associated with intellectual disability, autism spectrum disorder, and various dysmorphic features. However, the detailed genotype-phenotype correlations have yet to be fully elucidated. We report a four-year-old male patient who presented with developmental delay, impaired social interaction, repetitive behaviors, and language delay. Whole-exome sequencing identified a novel heterozygous frameshift variant in KMT5B (c.618del; p.Glu206Aspfs*7). Segregation analysis revealed that the patient's father also carried the same variant and exhibited intellectual disability and obsessive-compulsive disorder. This expands the mutational and phenotypic spectrum associated with KMT5B haploinsufficiency. It also underscores the potential for neuropsychiatric manifestations of KMT5B-related disorders to persist into adulthood, emphasizing the need for long-term follow-up and broader neurobehavioral assessment in affected individuals.
DOI: 10.6084/m9.figshare.30462827
title: Supplementary Material for: A Resident-led Quality Improvement Initiative to Accelerate Medical Therapy Implementation in Acute Heart Failure; ACCELERATE-HF

description: Introduction
Guideline-directed medical therapy (GDMT) optimization and effective de-congestion are known to improve outcomes in admitted heart failure (HF) patients, yet their implementation is suboptimal. Using a HF decision aid and point-of-care ultrasound (POCUS) at admission, this resident-led quality improvement (QI) initiative aimed to improve GDMT use and reduce HF readmissions.

Methods
This prospective, single-center QI initiative compared resident-performed POCUS and HF decision-aid use (the QI arm) with routine hospital care in admitted HF patients. Assignment to the QI arm was based on availability of residents trained to perform POCUS on admission. Primary outcome: 30-day hospital readmission; secondary outcomes: GDMT utilization using a standard score, adverse outcome occurrence, and 30-day mortality.

Results
The study was terminated early due to funding constraints. We enrolled 103 (42 in the QI arm) out of planned 254 patients. At discharge, the QI arm had a trend towards improvement in GDMT scores (+21±23% vs +12±24% in controls, p=0.106), in particular, a numerically higher proportion of patients in the QI arm were discharged on renin-angiotensin-aldosterone blockers (70.4% vs 51.4% of controls, p=.126). Adverse effect occurrence and 30-day outcomes (readmissions and mortality) were not significantly different between groups. Significantly more people in the QI arm had a transthoracic echocardiogram in the hospital (26 (65.0%) vs control: 21 (38.9%), p=.012).

Conclusion
This study showed that a resident-led QI initiative was feasible and resulted in modest improvement in GDMT use and echocardiography utilization but without effectively altering 30-day outcomes.
DOI: 10.6084/m9.figshare.30462827.v1
title: Supplementary Material for: A Resident-led Quality Improvement Initiative to Accelerate Medical Therapy Implementation in Acute Heart Failure; ACCELERATE-HF

description: Introduction
Guideline-directed medical therapy (GDMT) optimization and effective de-congestion are known to improve outcomes in admitted heart failure (HF) patients, yet their implementation is suboptimal. Using a HF decision aid and point-of-care ultrasound (POCUS) at admission, this resident-led quality improvement (QI) initiative aimed to improve GDMT use and reduce HF readmissions.

Methods
This prospective, single-center QI initiative compared resident-performed POCUS and HF decision-aid use (the QI arm) with routine hospital care in admitted HF patients. Assignment to the QI arm was based on availability of residents trained to perform POCUS on admission. Primary outcome: 30-day hospital readmission; secondary outcomes: GDMT utilization using a standard score, adverse outcome occurrence, and 30-day mortality.

Results
The study was terminated early due to funding constraints. We enrolled 103 (42 in the QI arm) out of planned 254 patients. At discharge, the QI arm had a trend towards improvement in GDMT scores (+21±23% vs +12±24% in controls, p=0.106), in particular, a numerically higher proportion of patients in the QI arm were discharged on renin-angiotensin-aldosterone blockers (70.4% vs 51.4% of controls, p=.126). Adverse effect occurrence and 30-day outcomes (readmissions and mortality) were not significantly different between groups. Significantly more people in the QI arm had a transthoracic echocardiogram in the hospital (26 (65.0%) vs control: 21 (38.9%), p=.012).

Conclusion
This study showed that a resident-led QI initiative was feasible and resulted in modest improvement in GDMT use and echocardiography utilization but without effectively altering 30-day outcomes.
DOI: 10.6084/m9.figshare.30462829
title: Additional file 1 of Investigating the causal role of the pediatric plasma proteome in Kawasaki disease: a Mendelian randomization study

description: Supplementary Material 1.
DOI: 10.6084/m9.figshare.30462829.v1
title: Additional file 1 of Investigating the causal role of the pediatric plasma proteome in Kawasaki disease: a Mendelian randomization study

description: Supplementary Material 1.
DOI: 10.6084/m9.figshare.30462836
title: Supplementary Material for: Inter-relationships of depression with cognitive function and their association with quality of life in older adults with hypertension: national survey findings from a network perspective

description: Objectives: Depression and cognitive declines are common and frequently co-occur among older adults with hypertension but their symptom-level relationships are poorly understood. This study explored inter-relationships between depressive symptoms and cognitive function as well as their associations with quality of life (QoL) in a national hypertension sample from China. 
Methods: Depressive symptoms, cognitive function, and global QoL were assessed utilizing Chinese versions of the 10-item Center for Epidemiological Studies Short Depression Scale (CESD-10), Mini Mental State Examination, and World Health Organization Quality of Life-brief version (WHOQOL-BREF), respectively. Central symptoms and bridge symptoms were identified with centrality strength and bridge strength indexes, while symptoms having links to QoL were analyzed via flow network analysis. 
Results: The study included 4,683 older adults. The prevalence of depression (CESD-10 total score ≥ 10) and cognitive impairment (MMSE total score &lt; 24) were 28.5% (95% CI= 27.2–29.8%) and 19.9% (n= 933; 95% CI= 18.8-21.1%), respectively. "Feeling blue/depressed" (CESD3) and "Language" (Lan) were identified as the most central (influential) symptoms in the network model. "Naming" (Nam) and "Language" (Lan) were identified as most important bridge symptoms. Finally, "Sleep disturbances" (CESD10) and "Hopelessness" (CESD5) had the strongest negative associations with QoL.
Conclusions: Targeting central and bridge symptoms (e.g., depressed emotions, language and naming ability) may provide pathways for addressing both depressive symptoms and cognitive declines among older adults with hypertension. Moreover, improving sleep quality and alleviating hopelessness could help to increase QoL in this population.
DOI: 10.6084/m9.figshare.30462836.v1
title: Supplementary Material for: Inter-relationships of depression with cognitive function and their association with quality of life in older adults with hypertension: national survey findings from a network perspective

description: Objectives: Depression and cognitive declines are common and frequently co-occur among older adults with hypertension but their symptom-level relationships are poorly understood. This study explored inter-relationships between depressive symptoms and cognitive function as well as their associations with quality of life (QoL) in a national hypertension sample from China. 
Methods: Depressive symptoms, cognitive function, and global QoL were assessed utilizing Chinese versions of the 10-item Center for Epidemiological Studies Short Depression Scale (CESD-10), Mini Mental State Examination, and World Health Organization Quality of Life-brief version (WHOQOL-BREF), respectively. Central symptoms and bridge symptoms were identified with centrality strength and bridge strength indexes, while symptoms having links to QoL were analyzed via flow network analysis. 
Results: The study included 4,683 older adults. The prevalence of depression (CESD-10 total score ≥ 10) and cognitive impairment (MMSE total score &lt; 24) were 28.5% (95% CI= 27.2–29.8%) and 19.9% (n= 933; 95% CI= 18.8-21.1%), respectively. "Feeling blue/depressed" (CESD3) and "Language" (Lan) were identified as the most central (influential) symptoms in the network model. "Naming" (Nam) and "Language" (Lan) were identified as most important bridge symptoms. Finally, "Sleep disturbances" (CESD10) and "Hopelessness" (CESD5) had the strongest negative associations with QoL.
Conclusions: Targeting central and bridge symptoms (e.g., depressed emotions, language and naming ability) may provide pathways for addressing both depressive symptoms and cognitive declines among older adults with hypertension. Moreover, improving sleep quality and alleviating hopelessness could help to increase QoL in this population.
DOI: 10.6084/m9.figshare.30462821
title: Additional file 1 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 1. Patient characteristics. Clinical and demographic information of the patients from whom all GSC cultures were obtained.
DOI: 10.6084/m9.figshare.30462821.v1
title: Additional file 1 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 1. Patient characteristics. Clinical and demographic information of the patients from whom all GSC cultures were obtained.
DOI: 10.6084/m9.figshare.30462824
title: Additional file 2 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 2. Primary and secondary antibodies. The complete list of the primary and secondary antibodies used in the study, with their host species and working dilutions.
DOI: 10.6084/m9.figshare.30462824.v1
title: Additional file 2 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 2. Primary and secondary antibodies. The complete list of the primary and secondary antibodies used in the study, with their host species and working dilutions.
DOI: 10.6084/m9.figshare.30462833
title: Additional file 4 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 4. Drug sensitivity scores.Complete data set of the drug sensitivity scores used for clustering the GSC cultures into highly drug-sensitive and highly drug-resistant groups.
DOI: 10.6084/m9.figshare.30462833.v1
title: Additional file 4 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 4. Drug sensitivity scores.Complete data set of the drug sensitivity scores used for clustering the GSC cultures into highly drug-sensitive and highly drug-resistant groups.
DOI: 10.6084/m9.figshare.30462851
title: Additional file 9 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 9. Annotation of somatic variants. Summary of detected mutations in all GSC cultures, including the affected gene, predicted consequence at the transcript and protein level, variant class, clinical tier, and the corresponding genomic change (GRCh38 coordinates). All variants identified are classified as Tier III, indicating variants of uncertain clinical significance.
DOI: 10.6084/m9.figshare.30462851.v1
title: Additional file 9 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 9. Annotation of somatic variants. Summary of detected mutations in all GSC cultures, including the affected gene, predicted consequence at the transcript and protein level, variant class, clinical tier, and the corresponding genomic change (GRCh38 coordinates). All variants identified are classified as Tier III, indicating variants of uncertain clinical significance.
DOI: 10.6084/m9.figshare.30462854
title: Additional file 10 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 10. Differentially expressed genes. Complete list of the differentially expressed genes between the drug-resistant and drug-sensitive GSC cultures.
DOI: 10.6084/m9.figshare.30462854.v1
title: Additional file 10 of Drug resistant glioblastoma stem cells exhibit enriched stemness signatures and share extracellular matrix overexpression

description: Additional file 10. Differentially expressed genes. Complete list of the differentially expressed genes between the drug-resistant and drug-sensitive GSC cultures.
DOI: 10.15468/dl.d5y956
title: Occurrence Download

description: A dataset containing 13 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "StateProvince is one of (Karnataka, Maharashtra, Telangana, Andhra Pradesh)",
 "TaxonKey is Devario malabaricus"
 ]
}

 The dataset includes 13 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003980-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.15468/dl.naj7bf
title: Occurrence Download

description: A dataset containing 71 species occurrences available in GBIF matching the query:
{
 "and" : [
 "GadmGid is CHN.28_1",
 "TaxonKey is Nepeta nuda"
 ]
}

 The dataset includes 71 records from 3 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0003981-251025141854904/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.30462958
title: Additional file 2 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 2: siRNA sequence of PADI2.
DOI: 10.6084/m9.figshare.30462958.v1
title: Additional file 2 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 2: siRNA sequence of PADI2.
DOI: 10.6084/m9.figshare.30462961
title: Additional file 3 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 3: Primers of related genes.
DOI: 10.6084/m9.figshare.30462961.v1
title: Additional file 3 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 3: Primers of related genes.
DOI: 10.6084/m9.figshare.30462964
title: Additional file 4 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 4: List of differently expressed genes between the MO and control groups.
DOI: 10.6084/m9.figshare.30462964.v1
title: Additional file 4 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 4: List of differently expressed genes between the MO and control groups.
DOI: 10.6084/m9.figshare.30462970
title: Additional file 5 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 5: Gene Ontology (GO) enrichment analysis of upregulated differentially expressed genes
DOI: 10.6084/m9.figshare.30462970.v1
title: Additional file 5 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 5: Gene Ontology (GO) enrichment analysis of upregulated differentially expressed genes
DOI: 10.6084/m9.figshare.30462973
title: Additional file 6 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 6: Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of upregulated differentially expressed genes
DOI: 10.6084/m9.figshare.30462973.v1
title: Additional file 6 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 6: Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of upregulated differentially expressed genes
DOI: 10.6084/m9.figshare.30462979
title: Additional file 8 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 8: Prediction of transcription factor-binding sites upstream of PADI2.
DOI: 10.6084/m9.figshare.30462979.v1
title: Additional file 8 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 8: Prediction of transcription factor-binding sites upstream of PADI2.
DOI: 10.6084/m9.figshare.30462985
title: Additional file 9 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 9: List of differentially expressed transcription factors between the MO and control groups.
DOI: 10.6084/m9.figshare.30462985.v1
title: Additional file 9 of PADI2 exacerbates Mycoplasma ovipneumoniae-induced lung injury in sheep by suppressing M2 macrophage polarization

description: Additional file 9: List of differentially expressed transcription factors between the MO and control groups.
DOI: 10.6084/m9.figshare.30462994
title: Additional file 1 of GRIN2B-related neurodevelopmental disorders: genotype-phenotype correlations and therapeutic implications

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.30462994.v1
title: Additional file 1 of GRIN2B-related neurodevelopmental disorders: genotype-phenotype correlations and therapeutic implications

description: Supplementary Material 1
DOI: 10.6084/m9.figshare.30462971
title: Additional file 15 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 15
DOI: 10.6084/m9.figshare.30462971.v1
title: Additional file 15 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 15
DOI: 10.6084/m9.figshare.30462974
title: Additional file 16 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 16
DOI: 10.6084/m9.figshare.30462974.v1
title: Additional file 16 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 16
DOI: 10.6084/m9.figshare.30462977
title: Additional file 17 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 17
DOI: 10.6084/m9.figshare.30462977.v1
title: Additional file 17 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 17
DOI: 10.6084/m9.figshare.30462980
title: Additional file 18 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 18
DOI: 10.6084/m9.figshare.30462980.v1
title: Additional file 18 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 18
DOI: 10.6084/m9.figshare.30462983
title: Additional file 19 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 19
DOI: 10.6084/m9.figshare.30462983.v1
title: Additional file 19 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 19
DOI: 10.6084/m9.figshare.30462986
title: Additional file 20 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 20
DOI: 10.6084/m9.figshare.30462986.v1
title: Additional file 20 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 20
DOI: 10.6084/m9.figshare.30462989
title: Additional file 21 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 21
DOI: 10.6084/m9.figshare.30462989.v1
title: Additional file 21 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 21
DOI: 10.6084/m9.figshare.30462992
title: Additional file 22 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 22
DOI: 10.6084/m9.figshare.30462992.v1
title: Additional file 22 of Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups

description: Supplementary Material 22